Veracyte, Inc. (VCYT)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K

$1,001–$15,000

Reported range · official band, not an exact amount

35 days

Disclosure lag

Traded

Mar 3, 2026

Disclosed

Apr 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 31, 2025Federal contract · $716K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $716K obligated to date
2. Jan 11, 2026Company filing · Form 8-K · ResultsReported its results
3. Jan 29, 2026Federal contract · $194K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $194K obligated to date
4. Feb 4, 2026Federal contract · $97K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $97K obligated to date
5. Feb 18, 2026CongressDisclosed purchase of VCYT — reported range $1,001 - $15,000
6. Feb 25, 2026Company filing · Form 8-K · ResultsReported its results
7. Feb 25, 2026Federal contract · $168K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $168K obligated to date
8. Feb 25, 2026Federal contract · $112K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $112K obligated to date
9. Mar 3, 2026 · this disclosureCongressDisclosed purchase of VCYT — reported range $1,001 - $15,000

What came next

1. Mar 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 16, 2026, Veracyte, Inc. (the “Company”) announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.”
2. May 5, 2026Company filing · Form 8-K · ResultsReported its results
3. May 29, 2026Federal contract · $97K obligatedDepartment of Veterans Affairs awarded VERACYTE, INC.: $97K obligated to date
4. Jun 10, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As further described in Item 5.07 to this Current Report on Form 8-K (this “Report”), on June 10, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Veracyte, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”) to increase the number of shares of the Company’s Common Stock, $0.001 par value, reserved for issuance…”

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Veracyte, Inc.

For Veracyte, Inc., OQRO holds 9 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VCYT page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

• House Clerk periodic transaction report at Globus Medical (GMED)Sep 10, 2026
• House Clerk periodic transaction report at Horace Mann Educators Corporation (HMN)Sep 10, 2026
• House Clerk periodic transaction report at Insulet Corporation (PODD)Sep 10, 2026
• House Clerk periodic transaction report at NXP Semiconductors (NXPI)Sep 10, 2026
• House Clerk periodic transaction report at Tesla (TSLA)Sep 10, 2026

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Veracyte, Inc.

• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordSep 29, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its VCYT page.